A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria
BACKGROUND: In low-income countries, viral load (VL) monitoring of antiretroviral therapy (ART) is rarely available in the public sector for HIV-infected adults or children. Using clinical failure alone to identify first-line ART failure and trigger regimen switch may result in unnecessary use of co...
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Journal article |
| 言語: | English |
| 出版事項: |
Public Library of Science
2013
|
| _version_ | 1826295676984623104 |
|---|---|
| author | Gilks, C Walker, A Munderi, P Kityo, C Reid, A Katabira, E Goodall, R Grosskurth, H Mugyenyi, P Hakim, J Gibb, D |
| author_facet | Gilks, C Walker, A Munderi, P Kityo, C Reid, A Katabira, E Goodall, R Grosskurth, H Mugyenyi, P Hakim, J Gibb, D |
| author_sort | Gilks, C |
| collection | OXFORD |
| description | BACKGROUND: In low-income countries, viral load (VL) monitoring of antiretroviral therapy (ART) is rarely available in the public sector for HIV-infected adults or children. Using clinical failure alone to identify first-line ART failure and trigger regimen switch may result in unnecessary use of costly second-line therapy. Our objective was to identify CD4 threshold values to confirm clinically-determined ART failure when VL is unavailable. METHODS: 3316 HIV-infected Ugandan/Zimbabwean adults were randomised to first-line ART with Clinically-Driven (CDM, CD4s measured but blinded) or routine Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s) in the DART trial. CD4 at switch and ART failure criteria (new/recurrent WHO 4, single/multiple WHO 3 event; LCM: CD4<100 cells/mm(3)) were reviewed in 361 LCM, 314 CDM participants who switched over median 5 years follow-up. Retrospective VLs were available in 368 (55%) participants. RESULTS: Overall, 265/361 (73%) LCM participants failed with CD4<100 cells/mm(3); only 7 (2%) switched with CD4≥250 cells/mm(3), four switches triggered by WHO events. Without CD4 monitoring, 207/314 (66%) CDM participants failed with WHO 4 events, and 77(25%)/30(10%) with single/multiple WHO 3 events. Failure/switching with single WHO 3 events was more likely with CD4≥250 cells/mm(3) (28/77; 36%) (p = 0.0002). CD4 monitoring reduced switching with viral suppression: 23/187 (12%) LCM versus 49/181 (27%) CDM had VL<400 copies/ml at failure/switch (p<0.0001). Amongst CDM participants with CD4<250 cells/mm(3) only 11/133 (8%) had VL<400 copies/ml, compared with 38/48 (79%) with CD4≥250 cells/mm(3) (p<0.0001). CONCLUSION: Multiple, but not single, WHO 3 events predicted first-line ART failure. A CD4 threshold 'tiebreaker' of ≥250 cells/mm(3) for clinically-monitored patients failing first-line could identify ∼80% with VL<400 copies/ml, who are unlikely to benefit from second-line. Targeting CD4s to single WHO stage 3 'clinical failures' would particularly avoid premature, costly switch to second-line ART. |
| first_indexed | 2024-03-07T04:04:43Z |
| format | Journal article |
| id | oxford-uuid:c5c20b7c-e5da-4b0b-8c4b-9307df082413 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:04:43Z |
| publishDate | 2013 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:c5c20b7c-e5da-4b0b-8c4b-9307df0824132022-03-27T06:33:17ZA single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteriaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c5c20b7c-e5da-4b0b-8c4b-9307df082413EnglishSymplectic Elements at OxfordPublic Library of Science2013Gilks, CWalker, AMunderi, PKityo, CReid, AKatabira, EGoodall, RGrosskurth, HMugyenyi, PHakim, JGibb, DBACKGROUND: In low-income countries, viral load (VL) monitoring of antiretroviral therapy (ART) is rarely available in the public sector for HIV-infected adults or children. Using clinical failure alone to identify first-line ART failure and trigger regimen switch may result in unnecessary use of costly second-line therapy. Our objective was to identify CD4 threshold values to confirm clinically-determined ART failure when VL is unavailable. METHODS: 3316 HIV-infected Ugandan/Zimbabwean adults were randomised to first-line ART with Clinically-Driven (CDM, CD4s measured but blinded) or routine Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s) in the DART trial. CD4 at switch and ART failure criteria (new/recurrent WHO 4, single/multiple WHO 3 event; LCM: CD4<100 cells/mm(3)) were reviewed in 361 LCM, 314 CDM participants who switched over median 5 years follow-up. Retrospective VLs were available in 368 (55%) participants. RESULTS: Overall, 265/361 (73%) LCM participants failed with CD4<100 cells/mm(3); only 7 (2%) switched with CD4≥250 cells/mm(3), four switches triggered by WHO events. Without CD4 monitoring, 207/314 (66%) CDM participants failed with WHO 4 events, and 77(25%)/30(10%) with single/multiple WHO 3 events. Failure/switching with single WHO 3 events was more likely with CD4≥250 cells/mm(3) (28/77; 36%) (p = 0.0002). CD4 monitoring reduced switching with viral suppression: 23/187 (12%) LCM versus 49/181 (27%) CDM had VL<400 copies/ml at failure/switch (p<0.0001). Amongst CDM participants with CD4<250 cells/mm(3) only 11/133 (8%) had VL<400 copies/ml, compared with 38/48 (79%) with CD4≥250 cells/mm(3) (p<0.0001). CONCLUSION: Multiple, but not single, WHO 3 events predicted first-line ART failure. A CD4 threshold 'tiebreaker' of ≥250 cells/mm(3) for clinically-monitored patients failing first-line could identify ∼80% with VL<400 copies/ml, who are unlikely to benefit from second-line. Targeting CD4s to single WHO stage 3 'clinical failures' would particularly avoid premature, costly switch to second-line ART. |
| spellingShingle | Gilks, C Walker, A Munderi, P Kityo, C Reid, A Katabira, E Goodall, R Grosskurth, H Mugyenyi, P Hakim, J Gibb, D A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria |
| title | A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria |
| title_full | A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria |
| title_fullStr | A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria |
| title_full_unstemmed | A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria |
| title_short | A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria |
| title_sort | single cd4 test with 250 cells mm3 threshold predicts viral suppression in hiv infected adults failing first line therapy by clinical criteria |
| work_keys_str_mv | AT gilksc asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT walkera asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT munderip asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT kityoc asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT reida asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT katabirae asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT goodallr asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT grosskurthh asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT mugyenyip asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT hakimj asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT gibbd asinglecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT gilksc singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT walkera singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT munderip singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT kityoc singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT reida singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT katabirae singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT goodallr singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT grosskurthh singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT mugyenyip singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT hakimj singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria AT gibbd singlecd4testwith250cellsmm3thresholdpredictsviralsuppressioninhivinfectedadultsfailingfirstlinetherapybyclinicalcriteria |